logo
  • About
    • MNI Leadership Board
  • HCP Resources
    • Education
    • HCP Consensus Statements from CJON
    • HCP Toolkits
    • ctDNA Testing for Response Monitoring
    • BRAF Testing
    • Care Step Pathways
    • Facebook Q&A Community
  • Videos
    • HCP Videos
    • Patient Videos
  • Decision Support Tools
    • Options for Stage II Melanoma
    • Options for Stage III Melanoma
    • Options for Stage IV Melanoma
  • Patient Resources
    • Patient Action Plans
    • Non-Invasive Evaluation Tools For Suspicious Spots
    • TIL Therapy
    • Side Effect Search
    • BRAF Q&A
    • ctDNA Testing Handout
    • Oncolytic Viruses
  • International Resources
    • Australia
    • Canada
    • France
    • Germany
    • Italy
    • Portugal
    • Spain
    • UK
  • About
    • MNI Leadership Board
  • HCP Resources
    • Education
    • HCP Consensus Statements from CJON
    • HCP Toolkits
    • ctDNA Testing for Response Monitoring
    • BRAF Testing
    • Care Step Pathways
    • Facebook Q&A Community
  • Videos
    • HCP Videos
    • Patient Videos
  • Decision Support Tools
    • Options for Stage II Melanoma
    • Options for Stage III Melanoma
    • Options for Stage IV Melanoma
  • Patient Resources
    • Patient Action Plans
    • Non-Invasive Evaluation Tools For Suspicious Spots
    • TIL Therapy
    • Side Effect Search
    • BRAF Q&A
    • ctDNA Testing Handout
    • Oncolytic Viruses
  • International Resources
    • Australia
    • Canada
    • France
    • Germany
    • Italy
    • Portugal
    • Spain
    • UK

Patient Action Plans

Here are customizable information packets on melanoma therapies that you can print for your patients. Please click on the drug you are interested in, and you will be directed to the printable action plan pages/sections, explanatory text, and instructions for customization.


  • BRAFTOVI™ (encorafenib)/MEKTOVI® (binimetinib)
  • COTELLIC® (cobimetinib)/ZELBORAF® (vemurafenib)
  • IMLYGIC® (talimogene laherparepvec; T-VEC)
  • KEYTRUDA® (pembrolizumab)
  • KEYTRUDA® QLEX (pembrolizumab and berahyaluronidase alfa-pmph)
  • KIMMTRAK® (tebentafusp-tebn)
  • OPDIVO® (nivolumab)
  • OPDIVO® (nivolumab)/YERVOY® (ipilimumab)
  • OPDIVO Qvantig™ (nivolumab + hyaluronidase-nvhy)
  • OPDUALAG™ (nivolumab)/(relatlimab)
  • TAFINLAR® (dabrafenib)/MEKINIST® (trametinib)
  • YERVOY® (ipilimumab)
Copyright ©2023- - The Melanoma Nursing Initiative. All rights reserved.
  • Terms
  • Privacy
  • News
  • Contact